ID   KPL-4
AC   CVCL_5310
SY   KPL4
DR   EFO; EFO_0006624
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-11134
DR   BioSample; SAMN03471036
DR   BioSample; SAMN03473250
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GEO; GSM590107
DR   GEO; GSM1374604
DR   PharmacoDB; KPL4_791_2019
DR   Progenetix; CVCL_5310
DR   Wikidata; Q54900438
RX   DOI=10.4172/2161-0681.1000119;
RX   PubMed=10070858;
RX   PubMed=15767549;
RX   PubMed=21247443;
RX   PubMed=23671654;
RX   PubMed=23784380;
RX   PubMed=25485619;
RX   PubMed=25960936;
RX   PubMed=35042871;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=KPL-4
CC   Part of: JFCR45 cancer cell line panel.
CC   Population: Japanese.
CC   Characteristics: ER-negative, PR-negative and ERBB2-positive.
CC   Doubling time: ~30 hours (PubMed=10070858).
CC   HLA typing: A*26:02,26:02; B*15:01,15:01; C*03:03,03:03; DQB1*03:02,03:02; DRB1*11:83,11:83 (PubMed=25960936).
CC   Microsatellite instability: Stable (MSS) (PubMed=23671654).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Derived from metastatic site: Pleural effusion.
ST   Source(s): PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 12
ST   D16S539: 12
ST   D18S51: 15
ST   D21S11: 29,32.2
ST   D3S1358: 16,17
ST   D5S818: 11,13
ST   D7S820: 9,10
ST   D8S1179: 11,16
ST   FGA: 19
ST   Penta D: 10,14
ST   Penta E: 11,12
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 14,19
DI   NCIt; C4001; Breast inflammatory carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 23-06-22; Version: 23
//
RX   DOI=10.4172/2161-0681.1000119;
RA   Robertson F.M., Chu K., Fernandez S.V., Mu Z.-M., Zhang X.-J., Liu H.,
RA   Boley K.M., Alpaugh R.K., Ye Z.-M., Wright M.C., Luo A.Z., Oraes R.,
RA   Wu H., Zook M., Barsky S.H., Krishnamurthy S., Cristofanilli M.;
RT   "Genomic profiling of pre-clinical models of inflammatory breast cancer
RT   identifies a signature of epithelial plasticity and suppression of
RT   TGFbeta signaling.";
RL   J. Clin. Exp. Pathol. 2:119.1-119.11(2012).
//
RX   PubMed=10070858; DOI=10.1038/sj.bjc.6690114;
RA   Kurebayashi J., Otsuki T., Tang C.K., Kurosumi M., Yamamoto S.,
RA   Tanaka K., Mochizuki M., Nakamura H., Sonoo H.;
RT   "Isolation and characterization of a new human breast cancer cell
RT   line, KPL-4, expressing the Erb B family receptors and interleukin-6.";
RL   Br. J. Cancer 79:707-717(1999).
//
RX   PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234;
RA   Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y.,
RA   Yamori T.;
RT   "Chemosensitivity profile of cancer cell lines and identification of
RT   genes determining chemosensitivity by an integrated bioinformatical
RT   approach using cDNA arrays.";
RL   Mol. Cancer Ther. 4:399-412(2005).
//
RX   PubMed=21247443; DOI=10.1186/gb-2011-12-1-r6;
RA   Edgren H., Murumagi A., Kangaspeska S., Nicorici D., Hongisto V.,
RA   Kleivi K., Rye I.H., Nyberg S., Wolf M., Borresen-Dale A.-L.,
RA   Kallioniemi O.-P.;
RT   "Identification of fusion genes in breast cancer by paired-end
RT   RNA-sequencing.";
RL   Genome Biol. 12:R6.1-R6.13(2011).
//
RX   PubMed=23671654; DOI=10.1371/journal.pone.0063056;
RA   Lu Y.-H., Soong T.D., Elemento O.;
RT   "A novel approach for characterizing microsatellite instability in
RT   cancer cells.";
RL   PLoS ONE 8:E63056-E63056(2013).
//
RX   PubMed=23784380; DOI=10.1007/s10549-013-2600-4;
RA   Fernandez S.V., Robertson F.M., Pei J.-M., Aburto-Chumpitaz L., Mu Z.-M.,
RA   Chu K., Alpaugh R.K., Huang Y., Cao Y., Ye Z.-M., Cai K.Q., Boley K.M.,
RA   Klein-Szanto A.J., Devarajan K., Addya S., Cristofanilli M.;
RT   "Inflammatory breast cancer (IBC): clues for targeted therapies.";
RL   Breast Cancer Res. Treat. 140:23-33(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=35042871; DOI=10.1038/s41523-021-00379-6;
RA   Rypens C., Bertucci F., Finetti P., Robertson F., Fernandez S.V.,
RA   Ueno N., Woodward W.A., Van Golen K., Vermeulen P., Dirix L.,
RA   Viens P., Birnbaum D., Devi G.R., Cristofanilli M., Van Laere S.;
RT   "Comparative transcriptional analyses of preclinical models and
RT   patient samples reveal MYC and RELA driven expression patterns that
RT   define the molecular landscape of IBC.";
RL   NPJ Breast Cancer 8:12.1-12.12(2022).
//